Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for changeflow.com

EPO Patent Granted: DNA Chip for Dental Caries Bacteria

The European Patent Office has granted patent EP3597770B1 for a DNA chip designed to detect bacteria associated with dental caries. The patent, effective March 18, 2026, lists Kazuto Takayama as the inventor.

Routine Notice Healthcare
Favicon for changeflow.com

EPO Patent: Methods for Functional Maturation of iPSC and ESC Cardiomyocytes

The European Patent Office has granted patent EP3589299B1 for methods and systems for the functional maturation of induced pluripotent stem cells (iPSC) and embryonic stem cells (ESC) derived cardiomyocytes. This patent is effective March 18, 2026.

Routine Guidance Pharmaceuticals
Favicon for changeflow.com

EPO Patent Granted for Mobile Cell Separation Device and Method

The European Patent Office has granted patent EP3587561B1 for a device and method for separating mobile cells. The patent, listing Herberto Ernesto Héctor Repetto as the inventor, was published on March 18, 2026, and covers various IPC classifications related to cell separation and medical devices.

Routine Notice Healthcare
Favicon for changeflow.com

EPO Patent Grant EP3560519B1: Virus AAV/IGF2 Genetic Treatment Method

The European Patent Office has granted patent EP3560519B1 for a virus AAV/IGF2 genetic treatment method and its use in protein misfolding-related diseases. The patent was published on March 18, 2026, and covers specific genetic treatment applications.

Routine Rule Pharmaceuticals
Favicon for changeflow.com

EPO Patent Grant for Nematode Control Methods

The European Patent Office has granted patent EP3531835B1 for methods of controlling nematodes. The patent, which lists multiple inventors, covers specific materials and methods related to nematode control and is effective March 18, 2026.

Routine Rule Pharmaceuticals
Favicon for changeflow.com

EPO Patent Grant EP3538656B1 for Reducing ATXN3 Expression

The European Patent Office has granted patent EP3538656B1 for compounds designed to reduce ATXN3 expression. This patent covers specific chemical compounds and their use in treating conditions related to ATXN3. The grant is effective March 18, 2026.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Grant EP3521419B1 for Producing Brown Adipocytes

The European Patent Office has granted patent EP3521419B1 for a method of producing brown adipocytes and a related composition. The patent lists Murakami Yuta and others as inventors and covers various designated states within the European Union.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Grant EP3510146B1: Transcription Factors Control Stem Cell Differentiation

The European Patent Office has granted patent EP3510146B1 for a technology related to transcription factors controlling stem cell differentiation. The patent lists inventors Alex H.M. Ng, George M. Church, and Volker Busskamp. This grant signifies the official recognition of intellectual property rights for this specific biotechnological innovation.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Granted: Cell-Associated Heterologous Food Enzymes

The European Patent Office has granted patent EP3596200B1 for cell-associated heterologous food and/or feed enzymes. This patent, effective March 18, 2026, covers specific biotechnological applications in food production.

Routine Rule Food Safety
Favicon for changeflow.com

EPO Grants Patent for Antigen-Presenting Cell-Mimetic Scaffolds

The European Patent Office (EPO) has granted patent EP3484448B1 for antigen-presenting cell-mimetic scaffolds and methods for their creation and use. The patent was published on March 18, 2026, and lists Alexander Sing Cheung and David J. Mooney as inventors.

Routine Notice Pharmaceuticals

Showing 2351–2360 of 22,596 changes

1 234 235 236 237 238 2260

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.